Logo image of INO

INOVIO PHARMACEUTICALS INC (INO) Stock Fundamental Analysis

NASDAQ:INO - Nasdaq - US45773H4092 - Common Stock - Currency: USD

2.24  +0.02 (+0.9%)

After market: 2.28 +0.04 (+1.79%)

Fundamental Rating

2

Overall INO gets a fundamental rating of 2 out of 10. We evaluated INO against 572 industry peers in the Biotechnology industry. The financial health of INO is average, but there are quite some concerns on its profitability. INO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INO had negative earnings in the past year.
In the past year INO has reported a negative cash flow from operations.
In the past 5 years INO always reported negative net income.
In the past 5 years INO always reported negative operating cash flow.
INO Yearly Net Income VS EBIT VS OCF VS FCFINO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -105.43%, INO is doing worse than 77.62% of the companies in the same industry.
The Return On Equity of INO (-153.49%) is worse than 65.19% of its industry peers.
Industry RankSector Rank
ROA -105.43%
ROE -153.49%
ROIC N/A
ROA(3y)-73.52%
ROA(5y)-66.86%
ROE(3y)-105.65%
ROE(5y)-765.57%
ROIC(3y)N/A
ROIC(5y)N/A
INO Yearly ROA, ROE, ROICINO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INO Yearly Profit, Operating, Gross MarginsINO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

5

2. Health

2.1 Basic Checks

INO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for INO has been increased compared to 1 year ago.
INO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, INO has a worse debt to assets ratio.
INO Yearly Shares OutstandingINO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
INO Yearly Total Debt VS Total AssetsINO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -23.85, we must say that INO is in the distress zone and has some risk of bankruptcy.
INO has a Altman-Z score of -23.85. This is amonst the worse of the industry: INO underperforms 88.63% of its industry peers.
INO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -23.85
ROIC/WACCN/A
WACC9.37%
INO Yearly LT Debt VS Equity VS FCFINO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 3.88 indicates that INO has no problem at all paying its short term obligations.
INO has a Current ratio (3.88) which is comparable to the rest of the industry.
INO has a Quick Ratio of 3.88. This indicates that INO is financially healthy and has no problem in meeting its short term obligations.
INO has a Quick ratio (3.88) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.88
Quick Ratio 3.88
INO Yearly Current Assets VS Current LiabilitesINO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.34% over the past year.
The Revenue for INO has decreased by -76.14% in the past year. This is quite bad
INO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -51.34% yearly.
EPS 1Y (TTM)40.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.95%
Revenue 1Y (TTM)-76.14%
Revenue growth 3Y-51.76%
Revenue growth 5Y-51.34%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, INO will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.83% on average per year.
INO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 166.24% yearly.
EPS Next Y31%
EPS Next 2Y23.35%
EPS Next 3Y18.32%
EPS Next 5Y13.83%
Revenue Next Year-88.18%
Revenue Next 2Y56.45%
Revenue Next 3Y192.5%
Revenue Next 5Y166.24%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INO Yearly Revenue VS EstimatesINO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
INO Yearly EPS VS EstimatesINO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

INO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year INO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INO Price Earnings VS Forward Price EarningsINO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INO Per share dataINO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as INO's earnings are expected to grow with 18.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.35%
EPS Next 3Y18.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INOVIO PHARMACEUTICALS INC

NASDAQ:INO (2/21/2025, 8:00:01 PM)

After market: 2.28 +0.04 (+1.79%)

2.24

+0.02 (+0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners35.91%
Inst Owner Change-95.49%
Ins Owners0.58%
Ins Owner Change0%
Market Cap80.75M
Analysts78
Price Target9.69 (332.59%)
Short Float %14.17%
Short Ratio4.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.23%
Min EPS beat(2)-6.95%
Max EPS beat(2)23.41%
EPS beat(4)2
Avg EPS beat(4)-0.07%
Min EPS beat(4)-29.26%
Max EPS beat(4)23.41%
EPS beat(8)3
Avg EPS beat(8)-2.96%
EPS beat(12)4
Avg EPS beat(12)-6.59%
EPS beat(16)6
Avg EPS beat(16)-8.25%
Revenue beat(2)0
Avg Revenue beat(2)-58.95%
Min Revenue beat(2)-100%
Max Revenue beat(2)-17.89%
Revenue beat(4)0
Avg Revenue beat(4)-72.09%
Min Revenue beat(4)-100%
Max Revenue beat(4)-17.89%
Revenue beat(8)1
Avg Revenue beat(8)-24.54%
Revenue beat(12)3
Avg Revenue beat(12)88.81%
Revenue beat(16)4
Avg Revenue beat(16)78.61%
PT rev (1m)-10.94%
PT rev (3m)-10.94%
EPS NQ rev (1m)8.26%
EPS NQ rev (3m)16.13%
EPS NY rev (1m)2.76%
EPS NY rev (3m)9.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-70.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-61.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 396.31
P/FCF N/A
P/OCF N/A
P/B 1.1
P/tB 1.1
EV/EBITDA N/A
EPS(TTM)-4.51
EYN/A
EPS(NY)-2.95
Fwd EYN/A
FCF(TTM)-3.08
FCFYN/A
OCF(TTM)-3.07
OCFYN/A
SpS0.01
BVpS2.04
TBVpS2.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.43%
ROE -153.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.52%
ROA(5y)-66.86%
ROE(3y)-105.65%
ROE(5y)-765.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.61%
Cap/Sales 239.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.88
Quick Ratio 3.88
Altman-Z -23.85
F-Score2
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)23.17%
Cap/Depr(5y)26.62%
Cap/Sales(3y)39.12%
Cap/Sales(5y)32.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.95%
EPS Next Y31%
EPS Next 2Y23.35%
EPS Next 3Y18.32%
EPS Next 5Y13.83%
Revenue 1Y (TTM)-76.14%
Revenue growth 3Y-51.76%
Revenue growth 5Y-51.34%
Sales Q2Q%-100%
Revenue Next Year-88.18%
Revenue Next 2Y56.45%
Revenue Next 3Y192.5%
Revenue Next 5Y166.24%
EBIT growth 1Y25.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.49%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.17%
OCF growth 3YN/A
OCF growth 5YN/A